P. Abbink

发表

Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys

Jerome H. Kim, B. Korber, P. Earl, 2013, Cell.

Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR-/- Mice.

L. Tostanoski, D. Barouch, Malika Aid, 2019, Cell host & microbe.

Development and immune correlates of Zika virus vaccines

P. Abbink, Peter Abbink Devopment, ND Imune, 2018 .

Pathogenic Simian Immunodeficiency Virus Infection Is Associated with Expansion of the Enteric Virome

Larissa B. Thackray, K. Mansfield, J. Brenchley, 2012, Cell.

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers

Daniel W. Kulp, D. Irvine, R. Wyatt, 2019, Immunity.

Vaccine-induced protection from homologous Tier 2 simian-human immunodeficiency virus challenge in nonhuman primates

Daniel W. Kulp, D. Irvine, R. Wyatt, 2018 .

Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys

D. Montefiori, K. Mansfield, G. Landucci, 2008, Nature.

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys

Jeffrey M. Gerold, Jerome H. Kim, H. Schuitemaker, 2016, Nature.

Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial

Allan C. deCamp, A. Perelson, E. Giorgi, 2021, Nature Medicine.

Vaccine delivery with microneedle skin patches in nonhuman primates

D. Irvine, Heikyung Suh, P. Hammond, 2013, Nature Biotechnology.

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

B. Korber, J. Mascola, D. Burton, 2017, Science Translational Medicine.

Rapid development of a DNA vaccine for Zika virus

J. Mascola, T. Pierson, S. Higgs, 2016, Science.

Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys

Ruchi M. Newman, Todd M. Allen, T. Allen, 2017, Journal of Virology.

Protective Efficacy of a Single Immunization of a Chimeric Adenovirus Vector-Based Vaccine against Simian Immunodeficiency Virus Challenge in Rhesus Monkeys

S. Self, D. Montefiori, K. Mansfield, 2009, Journal of Virology.

Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys

K. Mansfield, M. Havenga, A. Lemckert, 2008, Journal of Virology.

Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

K. Mansfield, M. Havenga, A. Lemckert, 2007, Journal of Virology.

Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus

D. Burton, J. Lifson, Mark G. Lewis, 2016, Science.

Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C

G. Shaw, Hui Li, D. Barouch, 2020, Journal of Virology.

Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus Monkeys

K. Mansfield, M. Lifton, M. Havenga, 2005, Journal of Virology.

Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika‐specific antibodies

D. Barouch, Lauren Peter, E. Borducchi, 2020, American journal of reproductive immunology.

Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy

D. Irvine, J. Tregoning, D. Barouch, 2018, The Journal of Immunology.

NS1 DNA vaccination protects against Zika infection through T cell–mediated immunity in immunocompetent mice

N. Prow, D. Barouch, J. Hayball, 2019, Science Advances.

Therapeutic and Protective Efficacy of a Dengue Antibody Against Zika Infection in Rhesus Monkeys

G. Screaton, D. Barouch, W. Dejnirattisai, 2018, Nature Medicine.

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

Alison E Kosel, K. Meyer, M. Robb, 2017, The Lancet.

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors

D. Barouch, N. Provine, P. Abbink, 2018, Journal of Virology.

Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys

S. Warfield, Mark G. Lewis, O. Afacan, 2018, Cell.

Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge

H. Schuitemaker, L. van der Fits, F. Cox, 2018, PloS one.

Durability and correlates of vaccine protection against Zika virus in rhesus monkeys

Gregory D. Gromowski, Mark G. Lewis, Stephen J. Thomas, 2017, Science Translational Medicine.

Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan Africa

P. Jeena, G. Weverling, M. Havenga, 2006, Journal of Clinical Microbiology.

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

K. Mansfield, S. Buchbinder, M. Robb, 2011, Vaccine.

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

P. Sorger, R. Baric, M. Lifton, 2020, Science.

Integrated technology platform for accelerated discovery of antiviral antibody therapeutics

Cinque S. Soto, M. Diamond, S. Reed, 2020, bioRxiv.

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Jessica Jimenez, Galit Alter, Kayvon Modjarrad, 2016, Science.

Vaccine Protection Against Zika Virus from Brazil

Richard G. Jarman, Zhenfeng Li, Nelson L. Michael, 2016, Nature.

Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors

B. Korber, H. Virgin, K. Wagh, 2014, Journal of Virology.

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

K. Mansfield, M. Lifton, M. Havenga, 2006, Nature.

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

Jennifer A. Johnson, J. Goudsmit, D. Barouch, 2013, The Journal of infectious diseases.

Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques

R. Siliciano, G. Alter, D. Barouch, 2021, Nature Communications.

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers

Young Chan Kim, J. Huiskonen, D. Barouch, 2019, Pathogens.

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine

Conor P. Cahill, H. Schuitemaker, L. van der Fits, 2021, Annals of Internal Medicine.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector

Jennifer A. Johnson, B. Korber, P. Earl, 2018, The Journal of infectious diseases.

Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.

Jennifer A. Johnson, D. Milner, D. Barouch, 2015, The Journal of infectious diseases.

Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).

U. Reimer, H. Wenschuh, N. Frahm, 2013, The Journal of infectious diseases.

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys

H. Schuitemaker, U. Reimer, H. Wenschuh, 2015, Science.

Zika virus vaccines

D. Barouch, K. Stephenson, P. Abbink, 2018, Nature Reviews Microbiology.

Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors

Young Chan Kim, G. Screaton, A. Kohl, 2018, Nature Communications.

Zika virus vaccines

D. Barouch, K. Stephenson, P. Abbink, 2018, Nature Reviews Microbiology.

Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys

A. Perelson, K. Best, D. Barouch, 2017, Cell.

First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).

Jennifer A. Johnson, D. Barouch, M. Seaman, 2014, The Journal of infectious diseases.

Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys

G. Alter, R. Geleziunas, D. Barouch, 2018, Nature.

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

Allan C. deCamp, J. Mascola, R. Koup, 2022, Nature Medicine.

Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells

W. Haining, K. Yates, D. Barouch, 2016, The Journal of Immunology.

Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys

Jerome H. Kim, H. Schuitemaker, D. Stablein, 2011, Nature.

Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques

D. Lauffenburger, G. Alter, C. Linde, 2020, Cell.

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

B. Korber, J. Mascola, D. Burton, 2017, Science Translational Medicine.

Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy

M. Robb, N. Michael, R. Geleziunas, 2018, Nature Communications.

Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys

J. Mascola, M. Connors, R. Koup, 2017, Journal of Virology.

Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation

B. Keele, R. Geleziunas, D. Barouch, 2020, Nature Communications.

Lack of therapeutic efficacy of an antibody to α4β7 in SIVmac251-infected rhesus macaques

K. Reimann, B. Keele, R. Geleziunas, 2019, Science.

Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy

M. Robb, N. Michael, R. Geleziunas, 2018, Nature Communications.

Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys

Bette Korber, Michael S. Seaman, James J. Szinger, 2010, Nature Medicine.

Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics

Cinque S. Soto, M. Diamond, S. Reed, 2020, Nature Biomedical Engineering.

Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics

Larissa B. Thackray, Cinque S. Soto, M. Diamond, 2020, Nature Biomedical Engineering.

Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors

H. Virgin, M. Havenga, D. Barouch, 2018, Journal of Virology.

Adenovirus serotype 5 vaccine vectors trigger IL-27–dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function

D. Barouch, N. Provine, K. Stephenson, 2016, Science Immunology.

Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys

B. Keele, Bing Chen, D. Barouch, 2017, Nature Communications.

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines

Young Chan Kim, G. Screaton, R. Hewson, 2020, Vaccines.

Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques

Gregory D. Gromowski, Stephen J. Thomas, N. Michael, 2017, PLoS pathogens.

Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization

P. Shabram, D. Barouch, K. Stephenson, 2015, Clinical and Vaccine Immunology.

Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice

A. Tager, D. Barouch, M. Seaman, 2018, Journal of Virology.

Mucosal Trafficking of Vector-Specific CD4+ T Lymphocytes following Vaccination of Rhesus Monkeys with Adenovirus Serotype 5

K. Mansfield, D. Barouch, J. Whitney, 2010, Journal of Virology.

Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys

P. Abbink, H. Li, Elizabeth G. Rhee, 2012, Journal of Virology.

Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

R. Geleziunas, D. Barouch, S. Fischinger, 2018, Nature.

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1

J. Treanor, M. Havenga, D. Barouch, 2018, PloS one.

Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor

Weam I Zaky, Gregory D. Gromowski, Hongjun Bai, 2020, Nature Medicine.

Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

G. Alter, R. Geleziunas, D. Barouch, 2018, Nature.

Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivo

D. Barouch, Malika Aid, P. Abbink, 2019, PLoS pathogens.

Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences

Jerome H. Kim, J. Ananworanich, M. Robb, 2016, PLoS pathogens.

Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes.

Weam I Zaky, Gregory D. Gromowski, Hongjun Bai, 2023, Cell Reports.

Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice

N. Michael, M. Busch, D. Barouch, 2021, PLoS pathogens.

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

P. Zanotto, Stephen J. Thomas, G. Alter, 2016, Science.

Vaccine Protection Against Zika Virus from Brazil

Stephen J. Thomas, N. Michael, R. Jarman, 2016, Nature.

Mucosal Trafficking of Vector-Specific CD4+ T Lymphocytes following Vaccination of Rhesus Monkeys with Adenovirus Serotype 5

K. Mansfield, D. Barouch, J. Whitney, 2010, Journal of Virology.

Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors Recommended Citation

E. Borducchi, P. Abbink, Lori F. Maxfield, 2022 .